Incannex Healthcare (IXHL) Expected to Release Quarterly Earnings on Monday

Incannex Healthcare (NASDAQ:IXHL) is expected to issue its Q4 2026 results before the market opens on Monday, September 7th. Analysts expect the company to announce earnings of ($0.1350) per share and revenue of $0.20 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Wednesday, September 30, 2026 at 9:30 AM ET.

Incannex Healthcare Stock Performance

Shares of NASDAQ:IXHL opened at $3.24 on Friday. The company has a market cap of $38.77 million, a P/E ratio of -2.09 and a beta of 6.97. The stock’s 50-day moving average is $3.33 and its 200-day moving average is $3.75. Incannex Healthcare has a 52-week low of $2.49 and a 52-week high of $20.31.

Institutional Trading of Incannex Healthcare

Institutional investors have recently made changes to their positions in the business. Arete Wealth Advisors LLC raised its position in Incannex Healthcare by 88.7% in the fourth quarter. Arete Wealth Advisors LLC now owns 2,223,450 shares of the company’s stock worth $796,000 after purchasing an additional 1,044,862 shares in the last quarter. Jane Street Group LLC lifted its stake in Incannex Healthcare by 547.4% during the fourth quarter. Jane Street Group LLC now owns 1,491,835 shares of the company’s stock worth $534,000 after purchasing an additional 1,261,385 shares during the period. Virtu Financial LLC boosted its holdings in Incannex Healthcare by 87.3% during the fourth quarter. Virtu Financial LLC now owns 753,675 shares of the company’s stock valued at $270,000 after purchasing an additional 351,232 shares in the last quarter. Finally, LPL Financial LLC boosted its holdings in Incannex Healthcare by 639.1% during the fourth quarter. LPL Financial LLC now owns 335,373 shares of the company’s stock valued at $120,000 after purchasing an additional 290,000 shares in the last quarter. 0.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IXHL has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Incannex Healthcare from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Incannex Healthcare in a research report on Friday, July 17th. Finally, Alliance Global Partners initiated coverage on Incannex Healthcare in a research note on Monday, June 8th. They set a “buy” rating and a $18.00 price target on the stock. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $18.00.

About Incannex Healthcare

Incannex Healthcare Ltd is a clinical-stage biopharmaceutical company focused on developing novel therapies that combine cannabinoid and psychedelic compounds. Headquartered in Melbourne, Australia, with research operations in the United States, the company seeks to leverage the therapeutic potential of its proprietary formulations to address a range of medical conditions. Incannex is publicly traded on the NASDAQ under the ticker IXHL and maintains a presence in both Australia and North America.

The company’s research and development pipeline includes multiple product candidates in various stages of clinical evaluation.